摘要
恶性胰岛细胞瘤是一种少见但治疗效果欠佳的神经内分泌肿瘤.舒尼替尼作为新一代的酪氨酸激酶抑制剂,已被证实对于恶性胰岛细胞瘤具备较好的疗效.
Malignant islet cell tumor, a rare type of neuroendocrine carcinoma, biologically behaves in an aggressive way and is difficulty to be treated. Sunitinib malate, a novel tyrosine kinase inhibitor, demonstrates a high efficacy in treating malignant islet cell tumor as shown by promising results in recent trials.
出处
《中华内分泌代谢杂志》
CAS
CSCD
北大核心
2011年第7期618-620,共3页
Chinese Journal of Endocrinology and Metabolism
关键词
舒尼替尼
恶性胰岛细胞瘤
Sunitinib malate
Malignant islet cell tumor